3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
10
Melanoma
6
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
3
Sarcoma
3
Ovarian Neoplasms
3
Carcinoma, Merkel Cell
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Liver Neoplasms
1
Kidney Neoplasms
1
Inflammatory Breast Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Chondrosarcoma
1
Interventions
pembrolizumab
18
Nivolumab
12
atezolizumab
5
Ipilimumab
4
Cyclophosphamide
4
fludarabine
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Fluorodeoxyglucose F18
3
Docetaxel
3
Carboplatin
3
spartalizumab
2
cabozantinib
2
avelumab
2
aldesleukin
2
Specimen Handling
2
Interleukin-2
2
Immunoglobulin G
2
zanidatamab
1
veliparib
1
trastuzumab deruxtecan
1
tislelizumab
1
temsirolimus
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
regorafenib
1
poly ICLC
1
pemigatinib
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
poly ICLC
×
Breast
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled